Science Director: Nico Callewaert
The mission of the VIB-UGent Center for Medical Biotechnology pushes the boundaries of biomolecular / bioinformatics research and engineering technologies. We have a longstanding reputation in different fields of protein biology. Bringing together expertise in protein engineering and expression, interactomics, proteomics and bioinformatics enables a multi-disciplinary approach.
Our focus is to develop new and innovative molecular tools and technologies to challenge human health problems. An emerging and fascinating research theme at CMB is the development and production of new biopharmaceuticals and vaccines. CMB is currently working on new applications in tuberculosis research, cancer treatment, antiviral immunity and others.
We also believe it is important to educate and train the next generation of medical biotechnology researchers and inform the public on the impact of biotechnology on human health.
The VIB Center for Medical Biotechnology is active within VIB and the University of Ghent.
A strong incentive to bring CMB technologies to patients resulted in the creation of four spin-off companies; Devgen (acquired by Syngenta), Pronota (acquired by MyCartis) and Oxyrane, Orionis Biosciences .
Funding & partners
Our research is supported by the Flemish government and several (inter)national funding bodies but also by numerous charity organizations.
VIB-UGent for Medical Biotechnology
VIB-UGent Research Building